A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-EXPLORATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AMG 650 IN SUBJECTS WITH ADVANCED SOLID TUMORS
- Registry ID
- 20190131
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2022-06-27
- Completion date
- 2022-10-18
- Last update
- 2020-03-12
Conditions
- ENDOMETRIAL CANCER
- BREAST CANCER TRIPLE NEGATIVE
- METASTATIC SOLID TUMOURS
- ADVANCED SOLID TUMORS
- OVARIAN CANCER
Related clinical trials
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
- A PHASE II, MULTI-CENTER, MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF VOLRUSTOMIG AS MONOTHERAPY OR IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF GSK5533524 ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS, IN ADULT PARTICIPANTS WITH SELECTED ADVANCED SOLID TUMORS
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH RECURRENT ENDOMETRIAL CANCER
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
- A PHASE 1, 2-PART, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF THE ANTI-LY6E EXATECAN ANTIBODY-DRUG CONJUGATE M7437 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
View on source registry